Share Price and Basic Stock Data
Last Updated: November 3, 2025, 8:41 pm
| PEG Ratio | -2.95 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Tata Chemicals Ltd operates in the inorganic chemicals sector, focusing primarily on caustic soda and soda ash. As of the latest trading price of ₹904, the company’s market capitalization stood at ₹23,026 Cr. The revenue from operations for the financial year ending March 2023 recorded a significant increase to ₹16,789 Cr, up from ₹12,622 Cr in March 2022. This upward trajectory indicates a robust recovery and growth phase for the company, with trailing twelve-month (TTM) revenue at ₹14,817 Cr. Quarterly sales figures also reflect this positive trend, with the highest quarterly sales of ₹4,407 Cr reported in March 2023. However, subsequent quarters showed fluctuations, with sales declining to ₹3,998 Cr in September 2023, suggesting volatility in demand or pricing pressures in the market. Overall, Tata Chemicals has managed to maintain a substantial revenue generation capacity, positioning itself competitively within the sector.
Profitability and Efficiency Metrics
The profitability metrics of Tata Chemicals reveal a mixed performance. The operating profit margin (OPM) for the financial year ending March 2025 is reported at 13%, a decline from 23% in March 2023, indicating increased cost pressures or reduced pricing power. The net profit for the latest reported period stood at ₹387 Cr, with an earnings per share (EPS) of ₹9.23. The return on equity (ROE) was recorded at a mere 1.08%, indicating that shareholder returns are relatively low compared to typical sector norms. In terms of efficiency, the interest coverage ratio (ICR) stood at 3.87x, suggesting that the company can comfortably meet its interest obligations. However, the cash conversion cycle (CCC) of 53 days indicates that the company’s operational efficiency may be under pressure, particularly when compared to typical sector averages, which often hover around 30 to 45 days. This combination of declining margins with stable interest coverage presents a challenging scenario for sustained profitability.
Balance Sheet Strength and Financial Ratios
Tata Chemicals showcases a reasonably strong balance sheet, with total assets reported at ₹37,750 Cr and total liabilities at ₹36,711 Cr as of March 2025. The company’s reserves have increased to ₹21,339 Cr, indicating a solid capital base. The borrowings stood at ₹7,072 Cr, which corresponds to a low long-term debt-to-equity ratio of 0.19, reflecting prudent financial management. The current ratio is reported at 1.09, suggesting adequate liquidity to cover short-term obligations. However, the debt-to-equity ratio of 0.29 indicates some leverage, which could pose risks if market conditions deteriorate. The price-to-book value (P/BV) ratio is at 1.02x, aligning closely with industry averages, suggesting that the stock is fairly valued in relation to its net assets. Overall, while the balance sheet reflects stability, the company must navigate its leverage carefully to maintain financial health.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Tata Chemicals indicates a stable ownership structure with promoters holding 37.98% of the shares. Foreign institutional investors (FIIs) have reduced their holdings to 12.85%, down from 14.92% in September 2022, which may reflect a cautious outlook among international investors. Domestic institutional investors (DIIs) have increased their stake to 22.61%, indicating growing confidence from local institutions in the company’s long-term prospects. The public holding stands at 26.53%, with a total of 677,130 shareholders as of March 2025, suggesting a broad base of retail participation. This stable shareholding structure, coupled with increased DII interest, reflects a level of investor confidence in Tata Chemicals despite recent fluctuations in profitability and market conditions. Such dynamics can play a crucial role in influencing future stock performance and market perception.
Outlook, Risks, and Final Insight
The outlook for Tata Chemicals appears cautiously optimistic, supported by its strong market positioning and increasing revenue generation capacity. However, the company faces several risks, including fluctuating raw material prices and potential regulatory challenges that could impact profitability. The decline in operating margins and the increased cost pressures suggest that the company must enhance operational efficiency to sustain profitability. Additionally, the reduction in FII holdings could signal a need for the company to bolster investor relations and communicate its growth strategy effectively. If Tata Chemicals can navigate these challenges and maintain its revenue growth trajectory while improving operational efficiencies, it may reinforce investor confidence and drive long-term value creation. Overall, the company’s ability to adapt to market conditions will be key to its future success.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Tata Chemicals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Caprolactam Chemicals Ltd | 20.8 Cr. | 45.2 | 65.0/37.5 | 10.5 | 0.00 % | 0.48 % | 13.7 % | 10.0 | |
| Standard Industries Ltd | 120 Cr. | 18.6 | 31.1/17.4 | 20.4 | 0.00 % | 7.81 % | 10.5 % | 5.00 | |
| Gujarat Alkalies & Chemicals Ltd | 4,134 Cr. | 562 | 894/484 | 772 | 2.81 % | 0.34 % | 1.13 % | 10.0 | |
| GHCL Ltd | 5,953 Cr. | 620 | 779/511 | 10.4 | 378 | 1.93 % | 24.2 % | 18.6 % | 10.0 |
| Tata Chemicals Ltd | 22,298 Cr. | 875 | 1,159/756 | 68.4 | 877 | 1.26 % | 3.96 % | 1.20 % | 10.0 |
| Industry Average | 6,670.80 Cr | 451.80 | 45.23 | 390.98 | 1.04% | 7.11% | 8.14% | 9.17 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,995 | 4,239 | 4,148 | 4,407 | 4,218 | 3,998 | 3,730 | 3,475 | 3,789 | 3,999 | 3,590 | 3,509 | 3,719 |
| Expenses | 2,980 | 3,319 | 3,317 | 3,442 | 3,175 | 3,191 | 3,188 | 3,032 | 3,215 | 3,381 | 3,156 | 3,182 | 3,070 |
| Operating Profit | 1,015 | 920 | 831 | 965 | 1,043 | 807 | 542 | 443 | 574 | 618 | 434 | 327 | 649 |
| OPM % | 25% | 22% | 20% | 22% | 25% | 20% | 15% | 13% | 15% | 15% | 12% | 9% | 17% |
| Other Income | 71 | 102 | 30 | 86 | 67 | 187 | 98 | -861 | 116 | 152 | -10 | 29 | 138 |
| Interest | 80 | 86 | 107 | 133 | 123 | 145 | 132 | 130 | 133 | 145 | 148 | 137 | 147 |
| Depreciation | 213 | 218 | 227 | 234 | 229 | 234 | 246 | 271 | 273 | 277 | 280 | 293 | 280 |
| Profit before tax | 793 | 718 | 527 | 684 | 758 | 615 | 262 | -819 | 284 | 348 | -4 | -74 | 360 |
| Tax % | 20% | 5% | 19% | -1% | 23% | 20% | 26% | 3% | 33% | 23% | 425% | -34% | 12% |
| Net Profit | 637 | 680 | 425 | 692 | 587 | 495 | 194 | -841 | 190 | 267 | -21 | -49 | 316 |
| EPS in Rs | 23.12 | 24.65 | 15.35 | 27.83 | 20.88 | 16.80 | 6.20 | -33.36 | 5.89 | 7.61 | -2.08 | -2.20 | 9.89 |
Last Updated: August 1, 2025, 9:30 pm
Below is a detailed analysis of the quarterly data for Tata Chemicals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 3,719.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,509.00 Cr. (Mar 2025) to 3,719.00 Cr., marking an increase of 210.00 Cr..
- For Expenses, as of Jun 2025, the value is 3,070.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 3,182.00 Cr. (Mar 2025) to 3,070.00 Cr., marking a decrease of 112.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 649.00 Cr.. The value appears strong and on an upward trend. It has increased from 327.00 Cr. (Mar 2025) to 649.00 Cr., marking an increase of 322.00 Cr..
- For OPM %, as of Jun 2025, the value is 17.00%. The value appears strong and on an upward trend. It has increased from 9.00% (Mar 2025) to 17.00%, marking an increase of 8.00%.
- For Other Income, as of Jun 2025, the value is 138.00 Cr.. The value appears strong and on an upward trend. It has increased from 29.00 Cr. (Mar 2025) to 138.00 Cr., marking an increase of 109.00 Cr..
- For Interest, as of Jun 2025, the value is 147.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 137.00 Cr. (Mar 2025) to 147.00 Cr., marking an increase of 10.00 Cr..
- For Depreciation, as of Jun 2025, the value is 280.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 293.00 Cr. (Mar 2025) to 280.00 Cr., marking a decrease of 13.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 360.00 Cr.. The value appears strong and on an upward trend. It has increased from -74.00 Cr. (Mar 2025) to 360.00 Cr., marking an increase of 434.00 Cr..
- For Tax %, as of Jun 2025, the value is 12.00%. The value appears to be increasing, which may not be favorable. It has increased from -34.00% (Mar 2025) to 12.00%, marking an increase of 46.00%.
- For Net Profit, as of Jun 2025, the value is 316.00 Cr.. The value appears strong and on an upward trend. It has increased from -49.00 Cr. (Mar 2025) to 316.00 Cr., marking an increase of 365.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 9.89. The value appears strong and on an upward trend. It has increased from -2.20 (Mar 2025) to 9.89, marking an increase of 12.09.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:22 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15,885 | 17,204 | 14,873 | 10,346 | 10,270 | 10,337 | 10,357 | 10,200 | 12,622 | 16,789 | 15,421 | 14,887 | 14,817 |
| Expenses | 15,200 | 15,305 | 12,777 | 8,249 | 6,926 | 8,538 | 8,411 | 8,693 | 10,317 | 12,969 | 12,574 | 12,934 | 12,789 |
| Operating Profit | 686 | 1,900 | 2,096 | 2,097 | 3,344 | 1,799 | 1,945 | 1,506 | 2,305 | 3,820 | 2,847 | 1,953 | 2,028 |
| OPM % | 4% | 11% | 14% | 20% | 33% | 17% | 19% | 15% | 18% | 23% | 18% | 13% | 14% |
| Other Income | -154 | 183 | 210 | 293 | 262 | 785 | 6,480 | 254 | 486 | 218 | -521 | 287 | 309 |
| Interest | 579 | 461 | 525 | 297 | 326 | 354 | 342 | 367 | 303 | 406 | 530 | 563 | 577 |
| Depreciation | 471 | 463 | 526 | 512 | 518 | 568 | 666 | 759 | 806 | 892 | 980 | 1,123 | 1,130 |
| Profit before tax | -519 | 1,159 | 1,255 | 1,580 | 2,763 | 1,661 | 7,416 | 634 | 1,682 | 2,740 | 816 | 554 | 630 |
| Tax % | 56% | 30% | 20% | 22% | 2% | 17% | 3% | 31% | 16% | 11% | 47% | 30% | |
| Net Profit | -811 | 802 | 1,006 | 1,234 | 2,702 | 1,387 | 7,228 | 436 | 1,405 | 2,434 | 435 | 387 | 513 |
| EPS in Rs | -40.50 | 23.41 | 30.24 | 38.98 | 95.49 | 45.37 | 274.97 | 10.06 | 49.37 | 90.93 | 10.52 | 9.22 | 13.22 |
| Dividend Payout % | -25% | 53% | 33% | 28% | 23% | 28% | 4% | 99% | 25% | 19% | 143% | 119% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 198.89% | 25.44% | 22.66% | 118.96% | -48.67% | 421.12% | -93.97% | 222.25% | 73.24% | -82.13% | -11.03% |
| Change in YoY Net Profit Growth (%) | 0.00% | -173.45% | -2.77% | 96.30% | -167.63% | 469.79% | -515.09% | 316.22% | -149.01% | -155.37% | 71.09% |
Tata Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | 8% |
| 3 Years: | 6% |
| TTM: | -1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -8% |
| 5 Years: | -48% |
| 3 Years: | -40% |
| TTM: | -45% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 25% |
| 3 Years: | -6% |
| 1 Year: | -13% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 5% |
| 3 Years: | 5% |
| Last Year: | 1% |
Last Updated: September 5, 2025, 4:00 am
Balance Sheet
Last Updated: June 16, 2025, 12:09 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 |
| Reserves | 5,311 | 5,297 | 6,600 | 7,653 | 10,847 | 12,086 | 12,643 | 14,035 | 17,998 | 19,466 | 21,986 | 21,339 |
| Borrowings | 8,393 | 8,379 | 9,090 | 7,072 | 6,108 | 6,130 | 7,702 | 6,933 | 7,024 | 6,296 | 5,563 | 7,072 |
| Other Liabilities | 6,127 | 6,872 | 8,402 | 8,607 | 8,648 | 8,398 | 7,073 | 7,115 | 8,566 | 8,923 | 8,907 | 9,084 |
| Total Liabilities | 20,086 | 20,802 | 24,346 | 23,587 | 25,858 | 26,869 | 27,673 | 28,337 | 33,843 | 34,940 | 36,711 | 37,750 |
| Fixed Assets | 11,007 | 11,359 | 13,431 | 12,644 | 12,787 | 13,551 | 15,356 | 15,261 | 16,044 | 17,092 | 17,861 | 19,600 |
| CWIP | 468 | 189 | 350 | 333 | 409 | 774 | 835 | 1,094 | 1,668 | 2,410 | 2,217 | 1,913 |
| Investments | 441 | 443 | 2,188 | 2,787 | 2,840 | 5,615 | 4,285 | 5,816 | 7,683 | 7,448 | 9,739 | 9,144 |
| Other Assets | 8,171 | 8,811 | 8,377 | 7,822 | 9,822 | 6,929 | 7,198 | 6,167 | 8,448 | 7,990 | 6,894 | 7,093 |
| Total Assets | 20,086 | 20,802 | 24,346 | 23,587 | 25,858 | 26,869 | 27,673 | 28,337 | 33,843 | 34,940 | 36,711 | 37,750 |
Below is a detailed analysis of the balance sheet data for Tata Chemicals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 255.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 255.00 Cr..
- For Reserves, as of Mar 2025, the value is 21,339.00 Cr.. The value appears to be declining and may need further review. It has decreased from 21,986.00 Cr. (Mar 2024) to 21,339.00 Cr., marking a decrease of 647.00 Cr..
- For Borrowings, as of Mar 2025, the value is 7,072.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 5,563.00 Cr. (Mar 2024) to 7,072.00 Cr., marking an increase of 1,509.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 9,084.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8,907.00 Cr. (Mar 2024) to 9,084.00 Cr., marking an increase of 177.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 37,750.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 36,711.00 Cr. (Mar 2024) to 37,750.00 Cr., marking an increase of 1,039.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 19,600.00 Cr.. The value appears strong and on an upward trend. It has increased from 17,861.00 Cr. (Mar 2024) to 19,600.00 Cr., marking an increase of 1,739.00 Cr..
- For CWIP, as of Mar 2025, the value is 1,913.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,217.00 Cr. (Mar 2024) to 1,913.00 Cr., marking a decrease of 304.00 Cr..
- For Investments, as of Mar 2025, the value is 9,144.00 Cr.. The value appears to be declining and may need further review. It has decreased from 9,739.00 Cr. (Mar 2024) to 9,144.00 Cr., marking a decrease of 595.00 Cr..
- For Other Assets, as of Mar 2025, the value is 7,093.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,894.00 Cr. (Mar 2024) to 7,093.00 Cr., marking an increase of 199.00 Cr..
- For Total Assets, as of Mar 2025, the value is 37,750.00 Cr.. The value appears strong and on an upward trend. It has increased from 36,711.00 Cr. (Mar 2024) to 37,750.00 Cr., marking an increase of 1,039.00 Cr..
Notably, the Reserves (21,339.00 Cr.) exceed the Borrowings (7,072.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 678.00 | -7.00 | -7.00 | -5.00 | -3.00 | -5.00 | -6.00 | -5.00 | -5.00 | -3.00 | -3.00 | -6.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 74 | 73 | 88 | 74 | 46 | 51 | 56 | 50 | 56 | 57 | 45 | 47 |
| Inventory Days | 96 | 137 | 119 | 244 | 304 | 315 | 347 | 257 | 318 | 282 | 341 | 324 |
| Days Payable | 119 | 138 | 99 | 232 | 307 | 269 | 302 | 256 | 338 | 289 | 320 | 318 |
| Cash Conversion Cycle | 52 | 72 | 107 | 86 | 43 | 97 | 100 | 51 | 35 | 50 | 66 | 53 |
| Working Capital Days | 11 | -4 | 31 | -4 | 27 | -2 | -102 | 27 | -29 | 29 | -22 | -21 |
| ROCE % | 3% | 11% | 11% | 10% | 16% | 9% | 36% | 4% | 8% | 12% | 8% | 4% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Mid-Cap Opportunities Fund - Regular Plan | 4,260,000 | 0.74 | 437.95 | 4,260,000 | 2025-04-22 13:31:13 | 0% |
| Kotak Flexicap Fund - Regular Plan | 3,750,000 | 0.87 | 385.52 | 3,750,000 | 2025-04-22 03:17:28 | 0% |
| Kotak Equity Opportunities Fund - Regular Plan | 2,064,884 | 1.16 | 212.28 | 2,064,884 | 2025-04-22 17:25:36 | 0% |
| Nippon India Growth Fund | 1,561,427 | 0.66 | 160.52 | 1,561,427 | 2025-04-22 17:25:36 | 0% |
| DSP Mid Cap Fund | 1,382,053 | 0.86 | 142.08 | 1,382,053 | 2025-04-22 03:17:28 | 0% |
| DSP Equity Opportunities Fund | 717,459 | 0.69 | 73.76 | 717,459 | 2025-04-22 17:25:36 | 0% |
| HDFC Large and Mid Cap Fund - Regular Plan | 508,000 | 0.33 | 52.22 | 508,000 | 2025-04-22 03:17:28 | 0% |
| Quant Active Fund | 217,000 | 0.27 | 22.31 | 217,000 | 2025-04-22 03:17:28 | 0% |
| Edelweiss Arbitrage Fund | 149,600 | 0.19 | 15.38 | 149,600 | 2025-04-22 03:17:28 | 0% |
| Kotak Multicap Fund | 143,500 | 0.17 | 14.75 | 143,500 | 2025-04-22 03:17:28 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 9.23 | 10.52 | 90.95 | 49.37 | 10.06 |
| Diluted EPS (Rs.) | 9.23 | 10.52 | 90.95 | 49.37 | 10.06 |
| Cash EPS (Rs.) | 53.18 | 52.82 | 130.43 | 77.91 | 45.91 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 846.82 | 906.43 | 809.49 | 751.80 | 594.25 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 846.82 | 906.43 | 809.49 | 751.80 | 594.25 |
| Revenue From Operations / Share (Rs.) | 583.80 | 604.75 | 658.39 | 495.33 | 400.27 |
| PBDIT / Share (Rs.) | 85.41 | 122.86 | 158.43 | 100.49 | 68.09 |
| PBIT / Share (Rs.) | 41.37 | 84.43 | 123.45 | 68.85 | 38.29 |
| PBT / Share (Rs.) | 14.39 | 29.88 | 107.45 | 56.53 | 23.87 |
| Net Profit / Share (Rs.) | 9.14 | 14.39 | 95.45 | 46.27 | 16.11 |
| NP After MI And SOA / Share (Rs.) | 9.21 | 10.51 | 90.86 | 49.35 | 10.06 |
| PBDIT Margin (%) | 14.63 | 20.31 | 24.06 | 20.28 | 17.01 |
| PBIT Margin (%) | 7.08 | 13.96 | 18.75 | 13.90 | 9.56 |
| PBT Margin (%) | 2.46 | 4.94 | 16.32 | 11.41 | 5.96 |
| Net Profit Margin (%) | 1.56 | 2.37 | 14.49 | 9.34 | 4.02 |
| NP After MI And SOA Margin (%) | 1.57 | 1.73 | 13.80 | 9.96 | 2.51 |
| Return on Networth / Equity (%) | 1.08 | 1.20 | 11.74 | 6.88 | 1.79 |
| Return on Capital Employeed (%) | 3.33 | 7.01 | 10.43 | 6.55 | 4.08 |
| Return On Assets (%) | 0.62 | 0.72 | 6.60 | 3.71 | 0.90 |
| Long Term Debt / Equity (X) | 0.19 | 0.13 | 0.28 | 0.20 | 0.36 |
| Total Debt / Equity (X) | 0.29 | 0.22 | 0.30 | 0.37 | 0.38 |
| Asset Turnover Ratio (%) | 0.39 | 0.42 | 0.48 | 0.40 | 0.14 |
| Current Ratio (X) | 1.09 | 1.05 | 1.66 | 1.23 | 1.49 |
| Quick Ratio (X) | 0.67 | 0.63 | 1.15 | 0.90 | 1.11 |
| Inventory Turnover Ratio (X) | 1.01 | 1.07 | 1.22 | 1.22 | 0.50 |
| Dividend Payout Ratio (NP) (%) | 162.55 | 166.41 | 13.72 | 20.25 | 109.30 |
| Dividend Payout Ratio (CP) (%) | 28.12 | 35.73 | 9.90 | 12.34 | 27.59 |
| Earning Retention Ratio (%) | -62.55 | -66.41 | 86.28 | 79.75 | -9.30 |
| Cash Earning Retention Ratio (%) | 71.88 | 64.27 | 90.10 | 87.66 | 72.41 |
| Interest Coverage Ratio (X) | 3.87 | 5.91 | 9.95 | 8.46 | 4.72 |
| Interest Coverage Ratio (Post Tax) (X) | 1.58 | 3.34 | 7.04 | 4.91 | 2.12 |
| Enterprise Value (Cr.) | 28656.05 | 32847.30 | 31130.10 | 31228.96 | 24062.00 |
| EV / Net Operating Revenue (X) | 1.92 | 2.13 | 1.85 | 2.47 | 2.36 |
| EV / EBITDA (X) | 13.16 | 10.48 | 7.71 | 12.20 | 13.87 |
| MarketCap / Net Operating Revenue (X) | 1.48 | 1.79 | 1.48 | 1.97 | 1.88 |
| Retention Ratios (%) | -62.55 | -66.41 | 86.27 | 79.74 | -9.30 |
| Price / BV (X) | 1.02 | 1.24 | 1.26 | 1.36 | 1.34 |
| Price / Net Operating Revenue (X) | 1.48 | 1.79 | 1.48 | 1.97 | 1.88 |
| EarningsYield | 0.01 | 0.01 | 0.09 | 0.05 | 0.01 |
After reviewing the key financial ratios for Tata Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 9.23. This value is within the healthy range. It has decreased from 10.52 (Mar 24) to 9.23, marking a decrease of 1.29.
- For Diluted EPS (Rs.), as of Mar 25, the value is 9.23. This value is within the healthy range. It has decreased from 10.52 (Mar 24) to 9.23, marking a decrease of 1.29.
- For Cash EPS (Rs.), as of Mar 25, the value is 53.18. This value is within the healthy range. It has increased from 52.82 (Mar 24) to 53.18, marking an increase of 0.36.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 846.82. It has decreased from 906.43 (Mar 24) to 846.82, marking a decrease of 59.61.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 846.82. It has decreased from 906.43 (Mar 24) to 846.82, marking a decrease of 59.61.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 583.80. It has decreased from 604.75 (Mar 24) to 583.80, marking a decrease of 20.95.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 85.41. This value is within the healthy range. It has decreased from 122.86 (Mar 24) to 85.41, marking a decrease of 37.45.
- For PBIT / Share (Rs.), as of Mar 25, the value is 41.37. This value is within the healthy range. It has decreased from 84.43 (Mar 24) to 41.37, marking a decrease of 43.06.
- For PBT / Share (Rs.), as of Mar 25, the value is 14.39. This value is within the healthy range. It has decreased from 29.88 (Mar 24) to 14.39, marking a decrease of 15.49.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 9.14. This value is within the healthy range. It has decreased from 14.39 (Mar 24) to 9.14, marking a decrease of 5.25.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 9.21. This value is within the healthy range. It has decreased from 10.51 (Mar 24) to 9.21, marking a decrease of 1.30.
- For PBDIT Margin (%), as of Mar 25, the value is 14.63. This value is within the healthy range. It has decreased from 20.31 (Mar 24) to 14.63, marking a decrease of 5.68.
- For PBIT Margin (%), as of Mar 25, the value is 7.08. This value is below the healthy minimum of 10. It has decreased from 13.96 (Mar 24) to 7.08, marking a decrease of 6.88.
- For PBT Margin (%), as of Mar 25, the value is 2.46. This value is below the healthy minimum of 10. It has decreased from 4.94 (Mar 24) to 2.46, marking a decrease of 2.48.
- For Net Profit Margin (%), as of Mar 25, the value is 1.56. This value is below the healthy minimum of 5. It has decreased from 2.37 (Mar 24) to 1.56, marking a decrease of 0.81.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.57. This value is below the healthy minimum of 8. It has decreased from 1.73 (Mar 24) to 1.57, marking a decrease of 0.16.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.08. This value is below the healthy minimum of 15. It has decreased from 1.20 (Mar 24) to 1.08, marking a decrease of 0.12.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.33. This value is below the healthy minimum of 10. It has decreased from 7.01 (Mar 24) to 3.33, marking a decrease of 3.68.
- For Return On Assets (%), as of Mar 25, the value is 0.62. This value is below the healthy minimum of 5. It has decreased from 0.72 (Mar 24) to 0.62, marking a decrease of 0.10.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 0.2. It has increased from 0.13 (Mar 24) to 0.19, marking an increase of 0.06.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.29. This value is within the healthy range. It has increased from 0.22 (Mar 24) to 0.29, marking an increase of 0.07.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.39. It has decreased from 0.42 (Mar 24) to 0.39, marking a decrease of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 1.5. It has increased from 1.05 (Mar 24) to 1.09, marking an increase of 0.04.
- For Quick Ratio (X), as of Mar 25, the value is 0.67. This value is below the healthy minimum of 1. It has increased from 0.63 (Mar 24) to 0.67, marking an increase of 0.04.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.01. This value is below the healthy minimum of 4. It has decreased from 1.07 (Mar 24) to 1.01, marking a decrease of 0.06.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 162.55. This value exceeds the healthy maximum of 50. It has decreased from 166.41 (Mar 24) to 162.55, marking a decrease of 3.86.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 28.12. This value is within the healthy range. It has decreased from 35.73 (Mar 24) to 28.12, marking a decrease of 7.61.
- For Earning Retention Ratio (%), as of Mar 25, the value is -62.55. This value is below the healthy minimum of 40. It has increased from -66.41 (Mar 24) to -62.55, marking an increase of 3.86.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 71.88. This value exceeds the healthy maximum of 70. It has increased from 64.27 (Mar 24) to 71.88, marking an increase of 7.61.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.87. This value is within the healthy range. It has decreased from 5.91 (Mar 24) to 3.87, marking a decrease of 2.04.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.58. This value is below the healthy minimum of 3. It has decreased from 3.34 (Mar 24) to 1.58, marking a decrease of 1.76.
- For Enterprise Value (Cr.), as of Mar 25, the value is 28,656.05. It has decreased from 32,847.30 (Mar 24) to 28,656.05, marking a decrease of 4,191.25.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.92. This value is within the healthy range. It has decreased from 2.13 (Mar 24) to 1.92, marking a decrease of 0.21.
- For EV / EBITDA (X), as of Mar 25, the value is 13.16. This value is within the healthy range. It has increased from 10.48 (Mar 24) to 13.16, marking an increase of 2.68.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.48. This value is within the healthy range. It has decreased from 1.79 (Mar 24) to 1.48, marking a decrease of 0.31.
- For Retention Ratios (%), as of Mar 25, the value is -62.55. This value is below the healthy minimum of 30. It has increased from -66.41 (Mar 24) to -62.55, marking an increase of 3.86.
- For Price / BV (X), as of Mar 25, the value is 1.02. This value is within the healthy range. It has decreased from 1.24 (Mar 24) to 1.02, marking a decrease of 0.22.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.48. This value is within the healthy range. It has decreased from 1.79 (Mar 24) to 1.48, marking a decrease of 0.31.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Tata Chemicals Ltd:
- Net Profit Margin: 1.56%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.33% (Industry Average ROCE: 7.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.08% (Industry Average ROE: 8.14%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.58
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.67
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 68.4 (Industry average Stock P/E: 45.23)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.29
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 1.56%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Inorganic - Caustic Soda/Soda Ash | Bombay House, 24, Homi Mody Street, Mumbai Maharashtra 400001 | investors@tatachemicals.com http://www.tatachemicals.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. S Padmanabhan | Chairman |
| Mr. R Mukundan | Managing Director & CEO |
| Mr. Modan Saha | Director |
| Mrs. Padmini Khare Kaicker | Independent Director |
| Mr. Rajiv Dube | Independent Director |
| Dr. C V Natraj | Independent Director |
| Mr. K B S Anand | Independent Director |
FAQ
What is the intrinsic value of Tata Chemicals Ltd?
Tata Chemicals Ltd's intrinsic value (as of 03 November 2025) is 583.13 which is 33.36% lower the current market price of 875.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 22,298 Cr. market cap, FY2025-2026 high/low of 1,159/756, reserves of ₹21,339 Cr, and liabilities of 37,750 Cr.
What is the Market Cap of Tata Chemicals Ltd?
The Market Cap of Tata Chemicals Ltd is 22,298 Cr..
What is the current Stock Price of Tata Chemicals Ltd as on 03 November 2025?
The current stock price of Tata Chemicals Ltd as on 03 November 2025 is 875.
What is the High / Low of Tata Chemicals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Tata Chemicals Ltd stocks is 1,159/756.
What is the Stock P/E of Tata Chemicals Ltd?
The Stock P/E of Tata Chemicals Ltd is 68.4.
What is the Book Value of Tata Chemicals Ltd?
The Book Value of Tata Chemicals Ltd is 877.
What is the Dividend Yield of Tata Chemicals Ltd?
The Dividend Yield of Tata Chemicals Ltd is 1.26 %.
What is the ROCE of Tata Chemicals Ltd?
The ROCE of Tata Chemicals Ltd is 3.96 %.
What is the ROE of Tata Chemicals Ltd?
The ROE of Tata Chemicals Ltd is 1.20 %.
What is the Face Value of Tata Chemicals Ltd?
The Face Value of Tata Chemicals Ltd is 10.0.